| Literature DB >> 26043224 |
Rohan Edmonds1, Brendan Burkett1, Anthony Leicht2, Mark McKean1.
Abstract
The purpose of this study was to a) determine the heart rate variability (HRV) and saliva markers of immunity (salivary immunoglobulin A; sIgA) and stress (salivary alpha-amylase; sAA) responses to chronic training in elite swimmers with a disability; and b) identify the relationships between HRV, sIgA, sAA and training volume. Eight members of a high performance Paralympic swimming program were monitored for their weekly resting HRV, sIgA and sAA levels in the 14 weeks leading up to a major international competition. The 14 week training program included aerobic, anaerobic, power and speed, and taper training phases, while also incorporating two swimming step tests and two swimming competitions. Specific time (root mean square of the successive differences; RMSSD) and frequency (high frequency normalized units [HFnu]) domain measures, along with non-linear indices (standard deviation of instantaneous RR variability; SD1 and short term fractal scaling exponent; α1) of HRV were used for all analyses with effects examined using magnitude-based inferences. Relationships between HRV and saliva markers were identified by Spearman rank rho (ρ) correlation coefficients. Compared with week 1, SD1 was very likely lower (96/4/0, ES = -2.21), while sAA was very likely elevated (100/0/0, ES = 2.32) at the beginning of week 7 for all athletes. The training program did not alter HRV or saliva whereas competition did. There were also no apparent differences observed for HRV, sIgA and sAA between each of the training phases during the 14 week swimming program. Correlations were observed between sAA and SD1 (ρ = -0.212, p<0.05), along with sAA and mean HR (ρ = 0.309, p<0.05). These results show that high level national competition influences depresses HRV (SD1) and increases saliva biomarkers of stress (sAA). It appears that a well-managed and periodised swimming program can maintain these indices within normal baseline levels. The study also highlighted the parasympathetic nervous system influence on sAA.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26043224 PMCID: PMC4456151 DOI: 10.1371/journal.pone.0127749
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Athlete Characteristics.
| Gender | Age (yrs) | Athlete (Classification) | Disability | National Experience (yrs) | |
|---|---|---|---|---|---|
|
| M | 23 | S8 | Amputee | 6 |
|
| M | 27 | S10 | Neuromuscular | 11 |
|
| M | 19 | S13 | Vision | 1 |
|
| M | 29 | SM10 | Amputee | 11 |
|
| M | 17 | S13 | Vision | 1 |
|
| M | 16 | S9 | Amputee | 1 |
|
| F | 19 | S14 | Intellectual | 2 |
|
| F | 15 | S8 | Cerebral Palsy | 1 |
aIPC Classification code
bYears competing as part of the national Paralympic swimming squad.
Average weekly kilometres completed during the 14 week monitoring period.
| Training Phase | Week | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | |
|
| 28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 34 | 43 | 47 | 48 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 45 | 48 | 48 | 45 | 47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 46 | 35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 28 | 29 |
|
|
|
|
|
|
| |||||||||||
|
|
|
| |||||||||||||
X indicates competition or swimming test
Mean values, variance from baseline, Cohen’s effect size (ES) and qualitative inferences for heart rate variability and saliva measures during the 14 week monitoring period.
| Week | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| %Δ | -0.7 | -0.7 | -3.1 | 0.4 | -2.2 | 1.3 | -0.6 | -0.8 | -3.4 | -1.4 | 3.4 | 1.9 | -0.3 | |
| (± 90% CI) | (± 4.9) | (± 3.2) | (± 5.3) | (± 6.3) | (± 4.9) | (± 6.5) | (± 3.8) | (± 8.6) | (± 2.9) | (± 4.5) | (± 8.0) | (± 8.7) | (± 9.5) | |
| ES | -0.04 | -0.04 | -0.17 | 0.02 | -0.12 | 0.07 | -0.03 | -0.04 | -0.21 | -0.08 | 0.19 | 0.10 | -0.02 | |
| QI |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| %Δ | 7.4 | 3.1 | 2.9 | -1.4 | -4.4 | -13.8 | -2.4 | 3.1 | -8.8 | 10.0 | -12.9 | -3.7 | 1.0 | |
| (± 90% CI) | (± 8.9) | (± 6.6) | (± 11.5) | (± 15.7) | (± 16.7) | (± 19.0) | (± 10.9) | (± 15.8) | (± 10.9) | (± 8.6) | (± 10.4) | (± 13.9) | (± 14.2) | |
| ES | 0.15 | 0.06 | 0.06 | -0.03 | -0.09 | -0.31 | -0.05 | 0.06 | -0.19 | 0.20 | -0.29 | -0.08 | 0.02 | |
| QI |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| %Δ | 3.1 | 7.3 | 5.7 | 5.5 | 4.3 | -0.3 | 10.2 | -0.5 | 2.7 | 2.5 | 10.5 | 4.4 | 7.9 | |
| (± 90% CI) | (± 6.0) | (± 4.7) | (± 11.9) | (± 5.3) | (± 9.1) | (± 12.8) | (± 8.7) | (± 10.8) | (± 9.1) | (± 9.2) | (± 9.7) | (± 9.3) | (± 8.7) | |
| ES | 0.11 | 0.25 | 0.20 | 0.19 | 0.15 | -0.01 | 0.35 | -0.02 | 0.10 | 0.09 | 0.36 | 0.15 | 0.27 | |
| QI |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| %Δ | -4.4 | -8.6 | -14.4 | -8.4 | -7.2 | -6.0 | -12.3 | 3.7 | -1.7 | -4.5 | -14.9 | -2.8 | -9.8 | |
| (± 90% CI) | (± 6.7) | (± 6.6) | (± 11.7) | (± 5.0) | (± 11.5) | (± 11.5) | (± 7.6) | (± 16.8) | (± 10.8) | (± 7.7) | (± 9.7) | (± 11.8) | (± 8.0) | |
| ES | -0.09 | -0.18 | -0.31 | -0.18 | -0.15 | -0.12 | -0.26 | 0.07 | -0.04 | -0.09 | -0.32 | -0.06 | -0.21 | |
| QI |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| %Δ | 21.6 | 3.6 | 17.5 | -14.5 | 5.6 | 13.3 | -6.1 | 16.0 | 12.9 | 29.4 | 22.7 | 19.9 | 28.0 | |
| (± 90% CI) | (± 17.6) | (± 20.9) | (± 19.1) | (± 27.5) | (± 29.6) | (± 25.5) | (± 23.6) | (± 28.6) | (± 25.9) | (± 24.2) | (± 26.2) | (± 24.4) | (± 22.3) | |
| ES | 0.74 | 0.13 | 0.61 | -0.60 | 0.21 | 0.48 | -0.24 | 0.56 | 0.46 | 0.98 | 0.78 | 0.69 | 0.94 | |
| QI |
|
|
|
|
|
|
|
|
|
|
|
|
| |
Root mean square of the successive differences—RMSSD; short term fractal scaling exponent— α1; high frequency normalised units—HF(nu); salivary immunoglobulin A—sIgA
%Δ—Percentage variance from baseline; CI—Confidence Interval; ES—Effect Size; QI—Qualitative Inference
Fig 1Percentage variance from the baseline (with 95% confidence interval) over the 14 week monitoring period for A) weekly heart rate variability, assessed by the standard deviation of short axis of the Poincare plot (SD1), and B) salivary alpha-amylase (sAA).
* indicates very likely lower (A) or very likely higher (B) than baseline.
Fig 2Relationship between salivary alpha-amylase (sAA) and A) weekly heart rate variability, assessed by the standard deviation of short axis of the Poincare plot (SD1), and B) weekly heart rate (HR).
ρ—Spearman’s rank rho correlation coefficient.